The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone.
D000328:Adult; D001943:Breast Neoplasms / Q000032:analysis / Q000097:blood / Q000188:drug therapy*; D002064:Buserelin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D017273:Goserelin; D006801:Humans; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D011374:Progesterone / Q000097:blood; D011960:Receptors, Estrogen / Q000032:analysis
D003692:Delayed-Action Preparations; D011960:Receptors, Estrogen; D017273:Goserelin; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin